Transforming Small-Molecule Nanoaggregation into Functional Drug Delivery Platforms

The development of stimuli-responsive nanoaggregates offers a transformative approach to cancer therapy, addressing the challenges of selectivity and efficacy. The spontaneous formation of nanoscale aggregates of small organic molecules through self-assembly is a major hurdle in early-stage drug discovery. However, this disadvantage can be transformed with a meticulous design into a functional drug delivery platform. Here, we report Nano-CC1-Acl, a nanoaggregate engineered for targeted anticancer activity. CC1 and CC1-Acl, benzimidazole derivatives, undergo self-assembly in aqueous environments to generate Nano-CC1 (235.2 ± 28.2 nm; IC50 > 100 μM) and Nano-CC1-Acl (110.6 ± 23.1 nm; IC50 = 2.88–3.40 μM) nanoaggregates. The IC50 value of Nano-CC1-Acl further decreases to 0.20 ± 0.16 μM in the presence of cysteine, a biothiol. Triggered by intracellular biothiols, Nano-CC1-Acl disassembles to release CC1, a potent microtubule-targeting agent that disrupts microtubule polymerization. Results presented here indicate that small molecule nanoaggregation can be utilized to develop functional drug delivery platforms.